Defined demand scales fast; new paradigms don't. Budget launches accordingly
This season's results split launches into two kinds: those that fill a clear slot and those that must build a market first. Ionis's reset on Tryngolza is the warning.
Two kinds of launch, two kinds of quarter
Read this batch of third-quarter reports side by side and the divide is not big versus small, or profitable versus loss-making. It is between launches that slot into demand that already exists and launches that must create a new way of treating patients.
The first group had a good quarter. Eton reported record product sales of $57.9 million, up 158% year over year, and said it passed its $200 million annualized run-rate goal five quarters early. It raised 2026 revenue guidance to more than $175 million from more than $145 million, and lifted its adjusted EBITDA target to more than 40%. Iovance posted record revenue of about $122 million, up about 80%, with gross margin around 60%. Keenova raised full-year net sales and adjusted EBITDA guidance on stronger XIAFLEX growth and Acthar Gel strength.
The second group got a reality check. Ionis lowered 2026 Tryngolza product sales guidance because the severe hypertriglyceridemia (sHTG) launch is ramping "more gradually than expected," which the company attributes to "the early dynamics of establishing a new treatment paradigm." That is the most useful sentence in the season, because it names the real constraint: in a large, underserved population, the product is only part of the launch. Prescribers, patients and systems also have to learn a new habit.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Adjusted EBITDA is the headline number. This earnings season shows why the bridge matters more
Harrow, Liquidia and CorMedix each reported strong operating metrics beside very different GAAP and guidance pictures. Leaders should judge the bridge between those numbers, not the number on top.
The real divide this earnings season is runway: who sets the timeline, and who is set by it
Revenue growth, settlements and trial milestones all matter, but the Q3 filings show the balance sheet decides who can act on them at a time of their own choosing.
Litigation is a launch cost, and earnings season is finally pricing it that way
Liquidia's $389.7 million settlement charge and Harrow's guidance reset show that the cost of defending a franchise belongs in the business case, not in a footnote below adjusted EBITDA.